Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin in Nanogam supplies a broad spectrum of IgG antibodies that bind to pathogens and toxins, neutralizing them. It also modulates the immune system by interacting with Fc receptors, helping to regulate abnormal immune responses and providing passive immunity.

The dose of Nanogam is individualized. The prescribing clinician determines the appropriate amount and infusion rate based on the patient’s weight, IgG level, and clinical condition. Dosing regimens are not standardized and should follow the prescriber’s instructions.

Safety data for Nanogam in pregnancy and lactation are limited. The product’s pregnancy category is unknown, so clinicians must weigh potential benefits against risks. Use is generally considered only if clearly needed, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Nanogam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Nanogam is a human normal immunoglobulin solution comparable to other IVIG products in providing IgG replacement. Differences may lie in manufacturing processes, concentration, and regulatory origin (EU). Clinicians choose a product based on availability, patient tolerance, and specific clinical guidelines.

Nanogam must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Nanogam is given as an intravenous infusion. The healthcare professional prepares the solution according to aseptic technique, selects an appropriate infusion set, and administers it over a period that may vary based on the patient’s tolerance and prescribed dose.

Serious risks include anaphylactic reactions, aseptic meningitis, acute renal failure, thrombotic events, hemolysis, and severe hypotension. Patients should be monitored closely during and after infusion, and any signs of these reactions require immediate medical attention.

Nanogam should not be used in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, as they are at increased risk for anaphylaxis. It is also contraindicated in patients with a history of severe hypersensitivity to immunoglobulin products.